文献速递临床试验与 GCP

高流量鼻导管治疗与持续气道正压治疗对儿科重症监护病房急性病患儿呼吸支持脱离的影响:一项随机临床试验

Effect of High-Flow Nasal Cannula Therapy vs Continuous Positive Airway Pressure Therapy on Liberation From Respiratory Support in Acutely Ill Children Admitted to Pediatric Critical Care Units: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2022-01-01

这项在24个儿科重症监护病房开展的实用、多中心、随机非劣效性试验纳入600名0至15岁急性病患儿,比较高流量鼻导管治疗(HFNC)与持续气道正压(CPAP)作为一线无创呼吸支持对脱离所有呼吸支持时间的影响。结果显示HFNC组脱离时间中位52.9小时,CPAP组47.9小时,校正风险比1.03(单侧97.5%CI 0.86-∞),满足非劣效性标准;HFNC组镇静使用、重症监护住院时长和急性住院时长显著更低。

要点

  • HFNC对比CPAP在脱离呼吸支持时间上满足非劣效性标准(校正HR 1.03,单侧97.5%CI 0.86-∞)。
  • HFNC组镇静使用率27.7% vs CPAP组37%(校正OR 0.59,95%CI 0.39-0.88)。
  • HFNC组重症监护住院时长5天 vs CPAP组7.4天(校正均差-3天,95%CI -5.1至-1天)。

核心结论

  • 在儿科重症监护病房经临床评估需要无创呼吸支持的急性病患儿中,与CPAP相比,HFNC在脱离呼吸支持时间上满足非劣效性标准。

研究设计与样本

  • 实用、多中心、随机非劣效性临床试验,在英国24个儿科重症监护病房开展。
  • 纳入600名0至15岁经临床评估需要无创呼吸支持的急性病患儿,2019年8月至2021年11月招募,末次随访于2022年3月完成。
  • 患儿按1:1随机开始HFNC(流量根据体重设定,n=301)或CPAP 7至8 cm H2O(n=299)。
  • 主要分析纳入573名儿童(HFNC组295名,CPAP组278名;中位年龄9个月;女孩226名[39%])。

主要发现

  • HFNC组脱离呼吸支持时间中位52.9小时(95%CI 46.0-60.9小时)vs CPAP组47.9小时(95%CI 40.5-55.7小时;绝对差5.0小时[95%CI -10.1至17.4小时];校正风险比1.03[单侧97.5%CI 0.86-∞])。
  • HFNC组镇静使用率27.7% vs CPAP组37%(校正比值比0.59[95%CI 0.39-0.88])。
  • HFNC组重症监护住院时长均值5天 vs CPAP组7.4天(校正均差-3天[95%CI -5.1至-1天])。
  • HFNC组急性住院时长均值13.8天 vs CPAP组19.5天(校正均差-7.6天[95%CI -13.2至-1.9天])。
  • 最常见不良事件为鼻部损伤:HFNC组6/295(2.0%)vs CPAP组18/278(6.5%)。

关键数值与推荐

  • 非劣效性界值为校正风险比0.75。
  • 主要结局为从随机化至脱离呼吸支持的时间,定义为开始连续48小时无任何形式呼吸支持(有创或无创)的起点。
  • HFNC组校正风险比1.03(单侧97.5%CI 0.86-∞)满足非劣效性标准。
  • 7个预设次要结局中3个在HFNC组显著更低:镇静使用(校正OR 0.59[95%CI 0.39-0.88])、重症监护住院时长(校正均差-3天[95%CI -5.1至-1天])、急性住院时长(校正均差-7.6天[95%CI -13.2至-1.9天])。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The optimal first-line mode of noninvasive respiratory support for acutely ill children is not known. OBJECTIVE: To evaluate the noninferiority of high-flow nasal cannula therapy (HFNC) as the first-line mode of noninvasive respiratory support for acute illness, compared with continuous positive airway pressure (CPAP), for time to liberation from all forms of respiratory support. DESIGN, SETTING, AND PARTICIPANTS: Pragmatic, multicenter, randomized noninferiority clinical trial conducted in 24 pediatric critical care units in the United Kingdom among 600 acutely ill children aged 0 to 15 years who were clinically assessed to require noninvasive respiratory support, recruited between August 2019 and November 2021, with last follow-up completed in March 2022. INTERVENTIONS: Patients were randomized 1:1 to commence either HFNC at a flow rate based on patient weight (n = 301) or CPAP of 7 to 8 cm H2O (n = 299). MAIN OUTCOMES AND MEASURES: The primary outcome was time from randomization to liberation from respiratory support, defined as the start of a 48-hour period during which a participant was free from all forms of respiratory support (invasive or noninvasive), assessed against a noninferiority margin of an adjusted hazard ratio of 0.75. Seven secondary outcomes were assessed, including mortality at critical care unit discharge, intubation within 48 hours, and use of sedation. RESULTS: Of the 600 randomized children, consent was not obtained for 5 (HFNC: 1; CPAP: 4) and respiratory support was not started in 22 (HFNC: 5; CPAP: 17); 573 children (HFNC: 295; CPAP: 278) were included in the primary analysis (median age, 9 months; 226 girls [39%]). The median time to liberation in the HFNC group was 52.9 hours (95% CI, 46.0-60.9 hours) vs 47.9 hours (95% CI, 40.5-55.7 hours) in the CPAP group (absolute difference, 5.0 hours [95% CI -10.1 to 17.4 hours]; adjusted hazard ratio 1.03 [1-sided 97.5% CI, 0.86-∞]). This met the criterion for noninferiority. Of the 7 prespecified secondary outcomes, 3 were significantly lower in the HFNC group: use of sedation (27.7% vs 37%; adjusted odds ratio, 0.59 [95% CI, 0.39-0.88]); mean duration of critical care stay (5 days vs 7.4 days; adjusted mean difference, -3 days [95% CI, -5.1 to -1 days]); and mean duration of acute hospital stay (13.8 days vs 19.5 days; adjusted mean difference, -7.6 days [95% CI, -13.2 to -1.9 days]). The most common adverse event was nasal trauma (HFNC: 6/295 [2.0%]; CPAP: 18/278 [6.5%]). CONCLUSIONS AND RELEVANCE: Among acutely ill children clinically assessed to require noninvasive respiratory support in a pediatric critical care unit, HFNC compared with CPAP met the criterion for noninferiority for time to liberation from respiratory support. TRIAL REGISTRATION: ISRCTN.org Identifier: ISRCTN60048867.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Ramnarayan P, Richards-Belle A, Drikite L, et al. Effect of High-Flow Nasal Cannula Therapy vs Continuous Positive Airway Pressure Therapy on Liberation From Respiratory Support in Acutely Ill Children Admitted to Pediatric Critical Care Units: A Randomized Clinical Trial. JAMA. 2022. PMID: 35707984. doi:10.1001/jama.2022.9615

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。